Wave Life Sciences Ltd. Ordinary Shares - WVE STOCK NEWS

Wave Life Sciences announced the pricing of its public offering of 8,333,334 ordinary shares at $12.00 per share, aiming for gross proceeds of approximately $100 million. The offering, slated to close on September 25, 2020, includes a 30-day option for underwriters to purchase an additional 1,250,000 shares. Jefferies, SVB Leerink, and Mizuho Securities are leading the offering, which is registered with the SEC. Funds raised are intended to advance Wave’s clinical-stage genetic medicines development.

Wave Life Sciences Ltd. (Nasdaq: WVE) announced an underwritten public offering of ordinary shares, hoping to raise capital for its clinical-stage genetic medicines initiatives. The company plans to grant underwriters a 30-day option to buy an additional 15% of shares sold. The offering's completion is subject to market conditions, with no assurance of final terms. The offering will be conducted via a previously filed shelf registration statement, and details will be available in a prospectus supplement filed with the SEC.

Wave Life Sciences (Nasdaq: WVE) has announced its participation in upcoming conferences to showcase its ADAR-mediated RNA editing technology and neurology programs targeting Huntington’s disease, ALS, and FTD. The company will present its first ADAR editing data involving ex vivo retina samples from non-human primates. Presentations will also cover Wave’s C9orf72 and SNP3 programs, with clinical trial applications expected in Q4 2020. These developments highlight Wave's commitment to advancing genetic medicines for debilitating diseases.

Wave Life Sciences Ltd. (Nasdaq: WVE) has announced that Paul Bolno, MD, MBA, the President and CEO, will present at the H.C. Wainwright 22^nd Annual Global Investment Conference on September 14, 2020, at 11:30 a.m. ET. Investors can access a live webcast of the presentation on the company’s Investor Relations page. Wave Life Sciences focuses on developing life-changing genetic medicines for severe diseases using its proprietary PRISM platform, which allows for the precise design and production of stereopure oligonucleotides.

Wave Life Sciences (Nasdaq: WVE) announced an upcoming Analyst and Investor Research Webcast on August 25, 2020, focusing on advancements in its neurology pipeline, including preclinical data for the C9orf72 program targeting ALS and FTD. Presentations will be made by key executives, highlighting strategy updates and new data on the PRISM platform. The event aims to showcase Wave's commitment to developing life-changing genetic treatments for severe diseases.

Wave Life Sciences (Nasdaq: WVE) has announced it will host a live webcast and conference call on August 10, 2020, at 8:30 a.m. ET to discuss its second quarter 2020 financial results and provide a business update. Interested parties can access the call via the Investor Relations section of the Wave Life Sciences website. The company, focused on delivering genetic medicines, continues to develop therapies for genetically defined diseases utilizing its proprietary PRISM^TM platform.

Wave Life Sciences (Nasdaq: WVE) announced that CEO Paul Bolno will present at the Jefferies 2020 Virtual Healthcare Conference on June 4, 2020, at 2:00 p.m. ET. The presentation will focus on the company's mission to develop life-changing genetic treatments using their proprietary PRISM platform. A live webcast will be available on the investor relations page of Wave's website, with a replay accessible for 90 days post-event. Wave Life Sciences is dedicated to addressing genetically defined diseases to improve patient futures.

Wave Life Sciences (Nasdaq: WVE) has appointed Dr. Kenneth Rhodes as Senior Vice President of Therapeutics Discovery. This newly established role will focus on advancing the company’s therapeutic pipeline, particularly in neurological diseases, utilizing the proprietary PRISM platform. Dr. Rhodes brings extensive experience from his previous roles at Yumanity Therapeutics and Biogen, emphasizing his capability to drive drug discovery initiatives. His appointment aligns with Wave's efforts to develop innovative treatments, including those for Huntington’s disease and related neurological conditions.

Wave Life Sciences (WVE) announced its Q1 2020 financial results, reporting a net loss of $47.5 million, up from $44.2 million in Q1 2019. Research and development expenses rose to $41.2 million, partially due to increased clinical activity related to Huntington's disease and a workforce reduction. The company maintains $120.9 million in cash, expecting to sustain operations through Q3 2021. Wave’s ongoing PRECISION-HD trials for Huntington's disease are progressing, and new data from its RNA-editing program demonstrate editing efficiencies of up to 50%.